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Abstract: Hyper-IgE syndrome is a primary immunodeﬁciency
marked by abnormalities in the coordination of cell–cell signaling with
the potential to affect TH17 cell, B cell, and neutrophil responses.
Clinical manifestations include recurrent skin and lung infections,
serum IgE elevation, connective tissue repair and development
alterations, and the propensity for vascular abnormalities and tumor
development. Signal transducer and activator of transcription 3
(STAT3) signaling, dedicator of cytokinesis 8 (DOCK8) signaling,
and tyrosine kinase 2 (TYK2) signaling alterations have been
implicated in 3 forms of hyper-IgE syndrome.
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SIGNAL TRANSDUCER AND ACTIVATOR OF
TRANSCRIPTION 3 SIGNALING
The STAT3 gene, located on chromosome 17q21, encodesa transcription factor that dimerizes with itself, signal
transducer and activator of transcription 1 (STAT1), or STAT4
after cognate receptor activation and translocates to the nucleus
to affect transcription in response to multiple cytokines.1 The
interleukin (IL)-6 family members (IL-6, IL-1, IL-31, LIF,
CNTF, CLC/CLF, NP, CT1, and OSM), IL-10 family members
(IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26), IL-12 family
members (IL-23 and IL-27), IL-21, granulocyte colony-
stimulating factor, and leptin signal through STAT3.2,3 Further-
more, STAT3 has been implicated in G protein–coupled
receptor signaling and in cellular homeostatic control mecha-
nisms involving mitochondrial regulation of reactive oxygen
species (ROS) generation.4,5 As a result, STAT3 mutation has
the potential for wide ranging effects on the immune system and
metabolically active cells, including cancer cells.
STAT3 mutations have been identiﬁed in the coiled-coil
domain (important for interactions with other proteins), the
DNA-binding domains (important for transcriptional regula-
tion), the Src homology 2 (SH2) domains (important in Stat
protein dimerization and receptor contacts), and the gene
splice sites/trans activation sites (associated with protein
interactions important in gene transcription)6,7 (Fig. 1). Dom-
inant negative mutations in this gene lead to the autosomal
dominant form of hyper-IgE syndrome (HIES) (AD-HIES)
and a marked reduction in TH17 cells.
7
AD-HIES in vitro studies reveal variably impaired neutro-
phil responses marked by diminished neutrophil chemoattractant
receptors FPR, CXCR1, and CXCR2.8 FPR is a high-afﬁnity
receptor for bacterial N-formyl peptides important for neutrophil
chemotaxis and microbicidal activity.8 CXCR1 and CXCR2
receptors are responsive to ELR1 CXC chemokine subfamily
members, including CXCL1, 6, 7, and 8.9–22 In addition to neu-
trophil trafﬁcking response alterations, signaling to neutrophils
is impaired. Minegishi et al23 demonstrated an inability of T cells
to induce skin keratinocyte and bronchial epithelial cell recruit-
ment of neutrophils with anti-staphylococcal molecules, such as
CXCL8. Furthermore, a reduction in TH17 cells can skew adap-
tive, innate immune system communication responses to Can-
dida. TH17 cytokines, IL-17 and IL-22, regulate antimicrobial
peptides, such as histatins and b-defensin-2.24 Deﬁcits of these
antimicrobial peptides may help to explain why saliva from sub-
jects with AD-HIES often has reduced candicidal activity than
controls.24 Additional innate immune response deﬁcits in
AD-HIES include altered toll-like receptor (TLR2) responses in
the absence of TH17 cell versus TLR2 signaling in the presence
of TH17 cell responses.
23
TH17 cell reduction associated with STAT3 deﬁciency
might be a generalizable phenomenon speciﬁc to T-cell
differentiation.25 Siegel et al25 demonstrated that AD-HIES
subjects had decreased central memory CD41 and CD81 T
cells and increased naive T cells, consistent with a proliferation
and differentiation defect from naive precursors. These
ﬁndings may corroborate with a propensity to develop
varicella zoster virus reactivation in AD-HIES.25
B-cell dysregulation associated with IgE elevation in
HIES is incompletely understood. IL-21 signals through
STAT1, STAT3, and STAT5. Studies with naive IL-21
receptor knockout mice demonstrate increased IgE levels
but low IgG1 levels.26 Human in vitro B-cell studies reveal
alternative IL-21, context dependent, IgE regulation with low
IgE levels in the context of IL-21 incubation with PHA and
IL-4, but increased IgE in the context of IL-21 incubation
with anti-CD40 and IL-4, suggesting that T-cell–B-cell path-
way miscommunication may play a role in IgE elevation.27 In
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addition to IgE alterations in AD-HIES, peripheral blood B
lymphocytes are skewed toward transitional and naive cells
with marked reduction in memory B cells independent of the
STAT3 mutation location.28
The percentage of peripheral blood memory B cells is
frequently reduced in AD-HIES.29 Furthermore, AD-HIES
subjects have defects in peripheral blood memory B-cell
subsets, characterized by multiparameter ﬂow cytometry as
CD38lowCD24hi.30 Further characterization of cells from this
AD-HIES cohort, in comparison with controls, demonstrated
decreased numbers of all B-cell subsets, both switched and
unswitched with the greatest decrease in the IgA1 switched
and IgM1 unswitched memory B-cell populations.30 Plasma
analysis revealed that STAT3-HIES patients had a statistically
signiﬁcant increase in B-cell-activating factor of the TNF family
(BAFF), a B-cell survival factor, expression versus controls,
which correlated with a decrease in BAFF receptor expression.30
Furthermore, a positive correlation between National Institutes
of Health (NIH) HIES scores and plasma BAFF scores was
identiﬁed.30 Most subjects in this cohort also had poor T-cell
dependent antibody responses to bacteriophage phiX174
primary and secondary immunizations.30 The authors comment
that these ﬁndings reﬂect both altered B cell–intrinsic and B
cell–extrinsic STAT3 signaling defects.30
Tissue remodeling proteins are altered in AD-HIES.31
Matrix metalloproteinases (MMP)-8 (important for contribution
to acute lung inﬂammation and tissue remodeling after acute
lung injury) and MMP-9 (important for vascular smooth muscle
cell migration, macrophage recruitment and elastin degradation)
are elevated 3-fold during periods free from infection in
AD-HIES versus controls.31 Furthermore, MMP-3 (important
for cardiovascular matrix remodeling) was lower in AD-HIES
subjects versus control subjects.31
In a mouse model, Stat3 inactivation in osteocytes and
osteoblasts results in bone mechanical alterations, including
decreased bone strength, mass, and load response generation,
as well as impairment in ROS regulation.32
These ﬁndings give further validation to previous
studies suggesting that STAT3 plays a role in regulating
cellular homeostasis through mitochondrial oxidative stress
and ROS responses.4,33
DEDICATOR OF CYTOKINESIS 8 SIGNALING
DOCK8 is located on chromosome 9p24.34 Loss of ded-
icator of cytokinesis 8 (DOCK8) protein function leads to the
most common form of autosomal recessive HIES (AR-HIES).
DOCK8 is in the family of guanine exchange factors that can
activate Rho GTPases, which include ras-related C3 botulinum
toxin substrate 1 (RAC1) and cell division control protein 42
homolog (CDC42).35 Both RAC1 and CDC42 mediate impor-
tant effects on actin cytoskeletal rearrangements, whereby
CDC42 plays a role in effects at the leading edge of cell remod-
eling resulting in ﬁlopodial protrusions, whereas RAC1 affects
lamellipodial protrusions.36 Rho GTPase family members can
affect STAT3 phosphorylation, directly or indirectly (however,
these interactions in DOCK8-deﬁcient patients have not been
reported to the authors’ knowledge).37–39 Dock8 deletions have
been identiﬁed in the Dock homology region 1 (DHR1) domain
[important for binding phosphatidylinositol (3,4,5)-triphosphate
(PIP3) membrane-rich regions, which assist in perimembrane
positional organization] and in the DHR2 domain (important for
binding to Rho family GTPases)40,41 (Fig. 2). Hence, DOCK8,
through interactions with Rho GTPases, may play an important
role in actin ﬁlament arrangement.40
B and T lymphocytes express the most DOCK8.42
Hence, DOCK8-mediated HIES is associated with immunolog-
ical effects that occur at multiple stages in T- and B-cell
development. Findings include reduced CD81 T-cell stimula-
tion and clonal proliferation.43 Furthermore, there is a paucity
of naive CD81CD45RA1CCR71 circulating T cells; to a lesser
degree, there is a decline in CD81CD45RA2CCR72/1
memory T cells and an increase in a senescent population
of effector memory CD45RA1 (TEMRA) cells with the
phenotype CD81CD571CX3CR11CD272CD282CD1272.42
Some patients with this condition may have diminished TH17
cell functional responses; however, these ﬁndings do not
appear as prominent as in AD-HIES.44 A mouse model with
a DHR2-deﬁcient, homozygous, null DOCK8 allele strain sug-
gests that the most profound T-cell effects are on CD41 and
CD81 long-lived memory T-cell survival.45 In a mouse model,
B-cell effects include an attenuated ability to form marginal
zone B cells and to maintain germinal center B cells with
resultant defects in high-afﬁnity antibody generation.45,46
Engelhardt et al40 postulate that derangement in cell cytoskel-
etal organization has the potential to affect immunologic syn-
apse formation.
TYROSINE KINASE 2 SIGNALING
Tyrosine kinase 2 (TYK2) is in the family of Janus
kinase molecules, of which there are 4 known in humans.
TYK2 is located on chromosome 19p13.2.47–49 TYK2 trans-
duces signals transmitted from type I interferon receptors (in-
terferon a and b), cytokine receptors sharing IL-12Rb1
subunit (IL-12, IL-23), cytokine receptors sharing a gp 130
subunit (IL-6, IL-10, CNTF, LIF, IL-11), and IL-13.50–58
The TYK2 protein includes a FERM domain (important in
localizing the protein to the plasma membrane),59,60 an SH2
domain (important in modulating regulation of intracellular
signaling cascades),61–64 and a kinase domain (important in
phosphorylation of target proteins, such as STAT proteins,
which can cause the affected protein to change cellular location
or can affect association with other proteins)65 (Fig. 3).
FIGURE 1. Organization of the
STAT3 protein.
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Homozygous deletion mutations have been identiﬁed
originating in the FERM domain and before the kinase
domain in 2 different individuals. In vitro human TYK2-
deﬁcient cells, from the FERM origination mutant cells,
stimulated with interferon a, did not lead to tyrosine phos-
phorylation of JAK1, STAT1, STAT2, STAT3, and
STAT4.66 Furthermore, stimulation by IL-6 and IL-10 did
not increase SOCS3 levels, a repressor of STAT3.66 TYK2
deﬁciency is associated with decreased TH1 differentiation
and increased TH2 differentiation postulated to be TYK2-
regulated IL-12 effects.66 T-cell replenishment with TYK2
restored IL-12 and interferon a signaling.66 In a mouse
model, impaired TYK2 signaling supported the human im-
paired TH1 response ﬁndings and demonstrated diminished
interferon g secretion by IL-12–stimulated splenocytes.67
Impaired TH1 ﬁndings might give further clues to suscepti-
bility to mycobacterial infections in this condition. The mouse
model also introduced the notion of impaired IL-17 responses
in TYK2-deﬁcient mice by IL-23–stimulated splenocytes,
which might explain impaired fungal responses identiﬁed in
this condition.67
CLINICAL PRESENTATION OF AD-HIES
AD-HIES typically presents in the neonate stage
marked by papular or pustular rashes that mimic acne,
eosinophilic dermatitis, or eczema. Lesions typically begin
on the head and scalp before progressing over the rest of the
body and frequently become superinfected with Staphylococ-
cus aureus, resulting in recurrent abscess formation. These
recurrent abscesses are pus ﬁlled but lack typical inﬂamma-
tory responses like warmth, erythema, and pain.68,69 Viral
skin infections are rare in AD-HIES.
Within the ﬁrst years of life, these patients also get
frequent pneumonias with S. aureus. Streptococcus pneumo-
niae and Haemophilus inﬂuenzae are the next most common
pathogens. Symptoms include purulent sputum, but fever is
typically absent. Infection may lead to lung parenchyma
destruction, bronchiectasis, and pneumatocele formation in
the majority of affected subjects.68,69
Once structural changes occur in the lung, susceptibility
to invasive mycotic infections can ensue as reported by Vinh
et al.70 Forty-four percent of patients with structural damage
in this cohort contracted at least one such infection.70 In
patients with pneumatoceles and bronchiectasis, Pseudomo-
nas aeruginosa and Aspergillus fumigatus are frequently
implicated pathogens. A study by Melia et al71 concluded
that subjects with lung parenchyma damage have increased
risk of infection by nontuberculous mycobacteria. Rarely,
infection progresses to massive hemoptysis.72
AD-HIES patients have prominent oral and facial
ﬁndings that develop from childhood through the teenage
years. Findings include facial asymmetry, prominent fore-
head, broad nose, deep eyes, rough facial skin, and retention
of primary teeth, which may cause impaction or a double row
of teeth (Figs. 4, 5).
On the hard palate, subjects may have ﬁbrotic bridges
that typically run anterior to posterior, which may or may not
have associated grooves or clefts. The tongue surface has
prominent ﬁssures and a deep midline cleft anterior to the
circumvallate papillae is common. This pattern of ﬁssures can
also be seen on the lips, cheeks, and mucosa, with prominent
keratotic striations.68 Mucocutaneous candidiasis is also com-
mon in affected patients.69 Salivary gland defects in antimi-
crobial proteins, b-defensin-2 and histatins, have been
attributed to reduced candidacidal responses.24
From adolescence onward, the skeletal manifestations
of this disorder become prominent. About 75% of HIES
teenagers develop scoliosis, which can be severe enough to
necessitate rod implantation (Fig. 6).
Severe osteopenia and osteoporosis is common in
affected subjects. Frequent fractures of long bones and ribs
are reported in approximately 50% of patients. These fractures
are not necessarily associated with osteopenia. In the third and
fourth decade, degenerative joint disease, often of the spine,
can become debilitating and requires surgical correction.68
Vascular manifestations of AD-HIES vary in location
and severity. Aortic aneurysm rupture has been reported.73,74
Coronary artery dilation and tortuosity appears common.75
Speciﬁcally, dilation of the left anterior descending coronary
artery followed by right coronary artery involvement with
prevalences of 51% and 25% was reported by Freeman
et al.75 In contrast, tortuosity appeared more common in the
right coronary artery versus the left anterior descending.75 In
this cohort, the ﬁndings suggested vessel dilation and tortu-
osity prevalence increased with age and occurred more often
in men.75 Coronary arteries typically lack evidence of athero-
sclerotic damage.76 Other reported vascular abnormalities
include patent ductus venosus, pseudoaneurysms, and supe-
rior vena cava syndrome.74 Central nervous system (CNS)–
reported abnormalities include vasculitis, leading to a right
parietal infarction and thrombosis of the left posterior inferior
cerebellar artery.74
Gastrointestinal (GI) manifestations of AD-HIES are rare.
One case report described a 26-year-old man with sigmoid
FIGURE 3. Organization of the TYK2
protein.
FIGURE 2. Organization of the
DOCK8 protein.
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diverticulitis that progressed to a pelvic abscess. Resolution
required drainage, intravenous antibacterial and antifungal
agents, and sigmoid colectomy for successful treatment.77 There
have been 2 published reports of spontaneous colonic perfora-
tions: one occurred in an 18-year-old man who developed cecal
perforation and the other involved an 8-year-old girl who
developed transverse colon perforation.78,79 Three cases of his-
toplasmosis of the GI tract have been reported. Two occurred in
teenage patients thought to have Crohn disease before pathol-
ogy revealed histoplasmosis and the other occurred in an adult
with recurrent colonic histoplasmosis.80,81
AD-HIES patients also have an increased risk of
developing lymphomas. This risk may be as high as 259-
fold over the general population.82 A review of 23 subjects
with lymphoma identiﬁed 6 with T-cell lymphomas, 13 with
B-cell lymphomas, and 4 with classic Hodgkin lymphomas.
Of the B-cell lymphomas, pathologic analysis revealed 6 as
diffuse large B-cell lymphomas and 3 as Burkitt lympho-
mas.83,84 Other reported lymphomas include peripheral T-cell
lymphomas and mantle cell lymphomas.84
CLINICAL PRESENTATION OF DOCK8 AR-HIES
Patients with DOCK8 immunodeﬁciency syndrome
(DIDS), the most common form of AR-HIES, have a slightly
different presentation from that described above (Table 1). The
severe eczema and recurrent skin infections or abscesses caused
by S. aureus are still prominent, but affected subjects have
a higher rate of viral infections, which include molluscum
contagiosum, herpes simplex virus, and varicella (Zhang,
Englehardt). Food and environmental allergies are common.40,43
Asthma, eosinophilic esophagitis, and anaphylaxis have also
been variably reported.40,43 Recurrent upper respiratory infec-
tions, such as otitis media, otitis externa, and sinusitis, are com-
mon, whereas mastoiditis and recurrent croup are rare.43
Although frequent pneumonias are still common in this group,
they typically do not result in pneumatoceles. Implicated lung
pathogens include S. pneumoniae,Haemophilus inﬂuenza, Pneu-
mocystis jiroveci, Proteus mirabilis, P. aeruginosa, Cryptococ-
cus, respiratory adenovirus, and respiratory syncytial virus.43,85
Mortality from sepsis is much higher in the DIDS patients.
The typical facial presentation of a broad nose, prom-
inent forehead, and facial asymmetry, as well as retention of
FIGURE 5. Retention of primary teeth in a patient with
AD-HIES.
FIGURE 6. Scoliosis in a patient with AD-HIES.
FIGURE 4. Facial features in AD-HIES.
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primary teeth, is absent. Scoliosis is rare in this subset.
Mucocutaneous candidiasis is common in DIDS.
There is an increase in neurologic manifestations in
DIDS, including facial paralysis, hemiplegia, and CNS vascu-
litis.85 Reported CNS infections include JC virus-associated
progressive multifocal leukoencephalopathy, and meningitis
associated with Cryptococcus and Haemophilus inﬂuenza.40,43
Cerebral vascular abnormalities are more common in this
group than in AD-HIES.74 In the CNS, ruptured cerebral
aneurysm and subarachnoid hemorrhage have resulted in death
before clinical diagnosis, but to our knowledge, this has only
been reported twice in the literature in AR-HIES.85 The dis-
covery of CNS vascular abnormalities may occur incidentally
after a stroke or hemiplegia and precipitating features include
under-perfusion of large arteries and diminished basal cerebral
artery caliber. Aneurysms of the ascending aorta and pericar-
ditis are described affecting the cardiovascular system.74
In the GI tract, salmonella enteritis and giardiasis have
been reported. Mortality from malignancy is far higher in
DIDS than in AD-HIES. Skin-originating cancers are more
common and include fatal metastatic squamous cell carci-
noma and fatal cutaneous T-cell lymphoma–leukemia.43 Bur-
kitt lymphoma has been rarely reported.40 Autoimmune
hemolytic anemia has also been reported.40
DIDS laboratory ﬁndings can reveal, in addition to
elevated IgE and eosinophilia seen in AD-HIES, low absolute
lymphocyte counts, low total T-cell counts, with low CD41 and
low CD81 counts but normal CD41 to CD81 ratio.40,43 Neu-
trophil and monocyte numbers are usually normal, whereas
natural killer cell and B cell levels are variable.40,43 IgG levels
can be normal or elevated, IgA levels are variable, IgE levels
are typically elevated, and IgM levels are usually low.40,43
CLINICAL PRESENTATION OF TYK2 AR-HIES
Two patients with TYK2 deﬁciency have been
reported.66,86 The 2 patients had homozygous mutations in
TYK2, but in different locations of the gene. Furthermore, the
patients were of different ethnic backgrounds and had varied
clinical symptoms. Both patients lacked features typical to
AD-HIES, such as skeletal or dental alterations and both
patients had susceptibility to intracellular Mycobacterium
bovis after Bacille Calmette–Geurin (BCG) vaccination, but
with variable severity. Both had episodes of cutaneous herpes
infection but with variable severity.
The patient with more severe infections was of Turkish
descent, had an early termination codon in TYK2 at amino acid
position 767 caused by a 9-base pair DNA deletion in exon 16,
had mildly elevated IgE (to a maximum of 218 IU/mL), no
atopy, asthma, skin candidiasis, boils, folliculitis, or cold
abscesses. This patient developed 2 disseminated infections
with intracellular organisms. Speciﬁcally, 6 months after
vaccination with BCG, he was noted to have axillary
lymphadenopathy at age 8 months. This infection relapsed
after treatment with isoniazid and became generalized at age 21
months, affecting the cervical, axillary, and inguinal lymph
nodes bilaterally. Laboratory assessment during chronic
infection demonstrated normal nitroblue tetrazolium test,
normal serum IgG, IgM, IgA, and mildly elevated IgE. He
had no relapse after 18 months of treatment. The patient was
subsequently infected at age 8, with the intracellular organism
Brucella spp after ingestion of unpasteurized cheese. The
patient was treated with a 6-week antibiotic course and was
found to have neurobrucellosis and pneumonia 1 month later.
The patient was severely debilitated after this episode with left
temporal, occipital, and bilateral parietal brain infarcts accom-
panied by sensorineural hearing loss and residual cognitive
impairment. At age 11, he had an episode of herpes zoster
involving the right maxillary branch of the trigeminal nerve.86
The patient with more mild infections was of Japanese
descent, had an early termination codon at amino acid
position 90 caused by a frame shift mutation at DNA coding
regions 70 to 89, had elevated IgE (2100 IU/mL), and
susceptibility to viruses, fungi, mycobacteria, and intracellu-
lar and extracellular bacteria. He was noted to have atopic
dermatitis–like rash in the ﬁrst month of life, skin abscesses,
oral candidiasis, recurrent otitis media, sinusitis, pneumonias,
molluscum contagiosum, and herpes simplex infection of the
skin and mucosa. He was also noted to develop 2 infections
with intracellular infections. The ﬁrst infection was to BCG at
age 22 months. The second infection was to non-typhi sal-
monella gastroenteritis at age 15. Peripheral blood laboratory
assessment revealed normal quantitative T, B, and natural
killer cells and normal neutrophil function. In vitro peripheral
blood mononuclear cell studies from the patient demonstrated
higher basal class I HLA expression, complete defects in type
I interferon responses, and failure to make interferon g after
IL-12 stimulation. In vitro studies also revealed blunted IL-6
and IL-10 responses with either absent or attenuated feedback
inhibition through suppressor of cytokine signaling (SOCS)3
expression after cytokine stimulation. In vitro studies also
revealed increased IL-5 and IL-13 when naive CD41 T cells
were stimulated with IL-2 and anti-CD3.66
DIAGNOSIS
Diagnosis of HIES is based on clinical and laboratory
ﬁndings originally described in a NIH HIES scoring criteria
TABLE 1. Distinguishing Features Comparing AD-HIES With






Viral skin infections 2 111 11
Pneumatoceles 11 2 2
Recurrent pneumonia 11 11 11
Sepsis mortality 1 111 111
Facial dysmorphic features 111 2 2
Primary tooth retention 111 2 2
Scoliosis 11 2 2
Neurologic manifestations 1 111 11
Cerebral vascular abnormalities 1 11 11
Food allergies 2 111 2
Environmental allergies 2 11
Decreased IgM 2 11 2
Atypical mycobacterial infections 2 2 11
Malignancy 1 111 ?
Lymphoma 1 1 ?
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consisting of 21 features.87 Although the NIH scale is sensi-
tive for the presence of HIES, it is not speciﬁc for the under-
lying mutation.88 However, analysis of mutations focused on
groups of mutations speciﬁcally localized to the STAT3 SH2-
and DNA-binding domains, the most common mutation
regions, identiﬁed that subjects with SH2 domain mutations
had a statistically signiﬁcant increase in scoliosis at a younger
age, high palate, increased intertalar distance, and increased
otitis and sinusitis.89 The same cohort had more deaths from
infection in subjects with DNA-binding domain mutations
versus subjects with SH2-binding domain mutation.89
The features identiﬁed in the NIH scale that are most
suggestive of a STAT3 mutation include: abscesses of inter-
nal organs, other severe infections, pneumatoceles, nail/
mucocutaneous candidiasis, bone fractures with minimal
trauma, scoliosis, and a family history of HIES.88 A subject
with a family history of HIES and a score .40 points is
highly likely to have a HIES genotype, but unlikely if they
score less than 20 points.90 Attempts to reﬁne more sensitive
and speciﬁc criteria for the diagnosis of speciﬁc forms of
HIES are ongoing.88
Revised clinical guidelines for the diagnosis of STAT3
mutant HIES have been proposed by Woellner et al.7 A pos-
sible diagnosis can be made with IgE levels $1000 IU/mL
plus a weighted score more than 30 based on 5 clinical ﬁnd-
ings: recurrent pneumonias, newborn rash, pathologic bone
fractures, facial appearance, and high palate. Probable diag-
nosis would include the above plus a family history of HIES
or lack of TH17 cells, and a deﬁnitive diagnosis would require
a known STAT3 mutation.7 While these clinical predictors
have been found useful in better classifying patients with
STAT3 mutations, the features unique to the AR-HIES sec-
ondary to DOCK8 were not addressed.
STAT3 mutation analysis is currently available commer-
cially and used in the research setting, given the large size of
the gene and expense of this endeavor. The use of high-
resolution polymerase chain reaction–based DNA-melting
assays to identify and screen patients for STAT3 mutations
are under investigation.91 This assay is quicker and cheaper
than genomic sequencing and screens for sequence variants
by DNA melting point changes. The variants can be subse-
quently conﬁrmed through targeted sequence analysis,
thereby lowering the cost in relation to complete genome
sequencing.91 This technique is reported to have 100% sen-
sitivity in a cohort of 16 patients for the identiﬁcation of
STAT3 mutations in AD-HIES patients and is expected to
identify such mutations in 90% of AD-HIES patients.91 To
date, there is no phenotype/genotype relationship among the
numerous STAT3 mutations identiﬁed.7
T-cell receptor excision circle (TREC) analysis in new-
born screening to detect severe combined immune deﬁciency
identiﬁed 3 consanguineous siblings with DIDS to have low
TRECs in one sibling and undetectable TRECs in the older
siblings aged 4 and 6.92 These ﬁndings raise the possibility for
early detection of DIDS and add this condition to the differential
diagnosis for absent or low TRECs on newborn screening.
Commercially available tests for diagnosis of DOCK8 and
TYK2 deﬁciency are limited. DIDS diagnostic considerations
include assessment for low serum IgM, low T-cell numbers, and
low T-cell proliferative responses. DOCK8 and TYK2 sequenc-
ing is available at specialized research laboratories.
TREATMENT
The importance of early recognition and treatment of S.
aureus and fungal infections is essential as these patients
often display fewer of the traditional ﬁndings and symptoms
associated with these infections.93 Although skin infections
are often treated with anti-staphylococcal antibiotic therapy,
antibacterial ointments, dilute bleach, or chlorinated water,
recrudescence is one of the classic signs of AD-HIES.93,94
Viral skin infections in DIDS are challenging and variably
responsive to anti-viral therapy. Respiratory infections can
lead to lung parenchymal damage; hence, eradication of pul-
monary infections is important. Targeted therapy based on
culture results could be considered given the risk for antimi-
crobial resistance with repeated antibiotic exposure. A high
index of suspicion for intracellular organism infections could
be considered in infections associated with TYK2 deﬁciency.
Hematopoietic cell transplantation (HCT) has been used
in treating both the autosomal recessive and autosomal
dominant forms of the disease. Limited information exists
regarding long-term outcome; however, many experts rec-
ommend transplantation for DIDS, as long-term outcome
without transplantation is poor owing to the risk for fatal
infections, malignancy risk and CNS infarction, and bleed-
ing.95 Successful long-term improvement, despite mixed
donor chimerism, has been reported in DIDS.95 Other reports
have been mixed. One case study reported successful engraft-
ment with the CD31 and CD151 cells being identiﬁed as
donor 21 days after HCT. After discharge, the subject did
not show evidence of any skin infections. Unfortunately,
long-term follow-up was unable to be performed as the pa-
tient was hospitalized and died 58 days after transplantation
due to Klebsiella pneumoniae bacteremia. The authors spec-
ulate that the transplant recipient’s congenital asplenia con-
tributed to morbidity and mortality.96 Another case series
reported the results of HCT on 2 patients with AR-HIES.
Although one patient had a complicated transplant course
with multiple ulcerative lesions, brain abscesses, and an acute
EBV infection after recovery and successful donor stem cell
engraftment, both patients demonstrated signiﬁcant clinical
improvement with resolution of their molluscum contagiosum
lesions and continued absence of cutaneous viral infections 2
and 4 years after transplantation. Laboratory assessment of
the patients’ immune function was normal with the exception
of low IgA levels in both patients.97
Some experts recommend using HCT in AD-HIES
patients with malignancy because other disease-related effects
can be managed without HCT. The role of HCT in the
treatment of AD-HIES is less consistent than reports on
patients with DIDS. One case series reported 2 subjects with
AD-HIES and non-Hodgkin lymphoma who underwent
allogeneic HCT with successful engraftment, and complete
donor chimerism was conﬁrmed by CD31 cell analysis. After
transplantation, both subjects demonstrated normalized IgE
levels, which remained normal for 14 and 10 years after trans-
plantation, respectively. In addition, neither subject has had
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recurrent infections requiring hospitalization, and both have
been free of skin infections.97 Osteoporosis, which was pres-
ent in one subject, resolved after transplantation. Furthermore,
the TH17 counts were normal.
4 This is in contrast with an
earlier report noting the failure of HCT to correct HIES in
a patient who relapsed 4 years after transplantation; however,
the mutation status of the patient was not addressed in the
original article.98
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